FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-2307

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bloom Burton Securities

            Deal Size: $10.2 million Upfront Cash: Undisclosed

            Deal Type: Financing February 13, 2020

            Details:

            The net proceeds of the Offering will be used to fund planned research and development activities for the Company’s four product candidates including ATI-2307, ATI-1701, ATI-1503 and ATI-1501.